SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as chatter increases around its role as a data provider, especially for Kalshi and its adoption. The community is speculating on potential integrations with major players and anticipating significant price movements. Some users highlight its utility and real-world asset (RWA) status as key drivers for future growth.

EVAA Protocol

EVAA Protocol ($EVAA) is trending as community members discuss recent upward price movement, with some calling for a continued run. Others point to the token being at a potential bottom after not participating in previous cycles. Recent short positions and TA analysis are also being heavily discussed.

DTE Energy Co. operates as a diversified energy company, which engages in the development and management of energy-related businesses and services. It operates through the following segments: Electric, Gas, DTE Vantage, Energy Trading, and Corporate and Other. The Electric segment consists of generation, purchase, distribution, and sale of electricity to residential, commercial, and industrial customers in southeastern Michigan. The Gas segment is involved in the purchase, storage, transportation, distribution, and sale of natural gas to residential, commercial, and industrial customers throughout Michigan, and the sale of storage and transportation capacity. The DTE Vantage segment focuses on projects that deliver energy and utility-type products and services to industrial, commercial, and institutional customers, produce reduced emissions fuel, and sell electricity and pipeline-quality gas from renewable energy projects. The Energy Trading segment covers energy marketing and trading operations. The Corporate and Other segment includes various holding company activities, holds certain non-utility debt, and holds certain investments, as well as funds supporting regional development and economic growth. The company was founded in January 1995 and is headquartered in Detroit, MI.

DTE Energy Co.

DTE Energy is trending amid discussions around earnings, investments in clean energy, and infrastructure upgrades. Community members are weighing the company's growth prospects against its debt and the impact of regulatory changes. Recent analyst ratings and price target adjustments are also contributing to the conversation.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending amid buyout speculation and positive sentiment around its MASH drug, Rezdiffra, especially following strong Q3 revenue despite wider-than-expected EPS loss. The community is actively discussing potential buyout prices and the company's strategic position in the MASH market, particularly as a potential combination therapy with GLP-1 agonists. Additionally, Madrigal's European launch of Rezdiffra is being closely watched as a key growth driver.

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insmed Inc

Insmed ($INSM) is trending as discussions revolve around its potential for growth, fueled by strong Brinsupri uptake and promising pipeline developments. The community highlights analysts' increased price targets and comparisons to blockbuster drugs like Humira, with many anticipating pivotal data releases and label expansions. However, some caution against the high valuation and potential risks associated with pharmaceutical stocks.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care is trending due to discussions around its Q3 earnings beat, driven by strong organic growth and pricing momentum in its Care Enablement segment. The community is focused on the potential impact of DefenCath, a treatment to reduce bloodstream infections, on Fresenius's mortality rates and profitability. There's also speculation regarding potential extensions to the TDAPA policy, impacting dialysis providers.

Investment Managers Series Trust II - Tradr 1.5X Short NVDA Daily ETF

Tradr 1.5X Short NVDA Daily ETF

Tradr 1.5X Short NVDA Daily ETF ($NVDS) is trending as traders speculate on potential pullbacks in NVDA and the broader tech sector. Community members are using $NVDS as a hedge against their long positions or as a way to capitalize on anticipated weakness in NVDA, with some noting overvaluation and potential for a correction.

Direxion Shares ETF Trust - Direxion Daily AAPL Bull 2X Shares

Direxion Daily AAPL Bull 1.5X Shares

Direxion Daily AAPL Bull 1.5X Shares ($AAPU) is trending as traders discuss potential upside for Apple and the broader market, with some noting technical indicators and potential catalysts like a new iPhone release. Community members are actively trading AAPU, looking for quick gains and swing opportunities, while also considering long-term positions in anticipation of future growth. Some traders are monitoring unusual options activity and considering strategies involving AAPU calls and puts.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending amid discussions about ETF possibilities and the impact of a potential hard cap on its token supply, with community members weighing the implications for staking rewards and long-term value. Aventus Network's integration with Polkadot is also generating buzz, highlighting interoperability and potential for growth within the ecosystem. Some traders express frustration with DOT's price action compared to other cryptocurrencies, while others remain optimistic about its future potential.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita (DVA) is trending as discussions revolve around reimbursement clarity and the potential impact of extending TDAPA (Transitional Drug Add-on Payment Adjustment). The community is focused on whether DaVita will adopt DefenCath, a product proven to reduce catheter-related bloodstream infections, with some suggesting its non-use raises questions about patient safety and cost control.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up Following Strong Earnings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up After Better-Than-Expected Earnings...

Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings

The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +20.78% and +3.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Floyd Petersen Sells 500 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 500 shares of the firm's stock in a transaction dated Monday, November 3rd. The shares were sold at an...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $12,635.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 500 shares of the firm's stock in a transaction on Monday, November 3rd. The stock was sold at an average...

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of +14.29% and +5.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?

CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.

How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?

CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Amphastar Pharmaceuticals Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

AMPH
Amphastar Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AMPH News

AMPHAmphastar Pharmaceuticals Inc